Possible effects of the new medicare reimbursement policy on African Americans with ESRD

Journal of the American Society of Nephrology

Volumn 20, Issue 7, 2009, Pages 1607-1613

  Ishani, Areef ^a,b   Guo, Haifeng ^a   Arneson, Thomas J ^a   Gilbertson, David T ^a   Mau, Lih Wen ^a   Li, Suying ^a   Dunning, Stephan ^a   Collins, Allan J ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

AFRICAN AMERICAN; AGED; ARTICLE; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; HEALTH CARE POLICY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 67649824189     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008080853     Document Type: Article

References (20)

1. Leavitt, MO. Report to Congress: A Design for a Bundled End Stage Renal Disease Prospective Payment System. Centers for Medicare and Medicaid Services. 2008. Available online at http://www.cms.hhs.gov/ ESRDGeneralInformation/ downloads/ESRDReportToCongress.pdf. Accessed January 27, 2009
2. Medicare Improvements for Patients and Providers Act of 2008 (Placed on Calendar in Senate). The Library of Congress. 2008. Available online at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110- cong-bills&docid=f:s3101pcs.txt.pdf. Accessed January 27, 2009
3. Powe NR, Griffiths RI, de LG, Anderson GF, Watson AJ, Greer JW, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 268: 1434-1440, 1992
4. U.S. Renal Data System: USRDS 2002 Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002, p 116
5. Lea JP, Norris K, Agodoa L: The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol 28: 732-743, 2008
6. KDOQI, National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S11-S145, 2006
7. Weisbord SD, Fried LF, Mor MK, Resnick AL, Kimmel PL, Palevsky PM, Fine MJ: Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy. J Natl Med Assoc 99: 1218-1226, 2007 (Pubitemid 350246903)
8. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60: 1875-1884, 2001 (Pubitemid 32999993)
9. Ward MM: Laboratory abnormalities at the onset of treatment of end-stage renal disease: Are there racial or socioeconomic disparities in care? Arch Intern Med 167: 2007
10. Volkova N, McClellan W, Soucie JM, Schoolwerth A: Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients. Nephrol Dial Transplant 21: 2202-2209, 2006 (Pubitemid 44295046)
11. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF: Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: Results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis 34: 756-759, 1999
12. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF Jr: Trends in anemia management among U.S. hemodialysis patients. J Am Soc Nephrol 13: 1288-1295, 2002 (Pubitemid 34441410)
13. Lacson E Jr, Rogus J, Teng M, Lazarus JM, Hakim RM: The association of race with erythropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis 52: 1104-1114, 2008
14. Beutler E, West C: Hematologic differences between African-Americans and whites: The roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood 106: 740-745, 2005 (Pubitemid 40981275)
15. Ifudu O, Chan E, Paul H, Mayers JD, Cohen LS, Brezsnyak WF, Herman AI, Avram MM, Friedman EA: Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients. ASAIO J 42: 146-149, 1996 (Pubitemid 26000026)
16. Sehgal AR: Impact of quality improvement efforts on race and sex disparities in hemodialysis. JAMA 289: 996-1000, 2003 (Pubitemid 37432930)
17. Jones-Burton C, Seliger SL, Brown J, Stackiewicz L, Hsu VD, Fink JC: Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. Nephrol Dial Transplant 20: 2739-2745, 2005 (Pubitemid 41672274)
18. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
19. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
20. Besarab A: Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl S13-S18, 2006 (Pubitemid 44561638)